DLBCL ARISING FROM FOLLICULAR LYMPHOMA
Clinical trials for DLBCL ARISING FROM FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DLBCL ARISING FROM FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for DLBCL ARISING FROM FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered donor cells take on Hard-to-Treat lymphomas
Disease control OngoingThis early-phase study tests a new treatment called P-CD19CD20-ALLO1 for people with certain types of B-cell lymphoma that have come back or not responded to standard therapy. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The m…
Matched conditions: DLBCL ARISING FROM FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Could a Pre-Treatment drug make CAR-T therapy more effective for tough lymphomas?
Disease control TerminatedThis study tests whether adding a drug called E7777 before standard CAR-T cell therapy can help people with relapsed or hard-to-treat large B-cell lymphoma. About 30 adults will receive E7777 followed by chemotherapy and an approved CAR-T product. The goal is to find the safest d…
Matched conditions: DLBCL ARISING FROM FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated May 12, 2026 13:51 UTC